The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Interleukin-22 levels in pediatric patients with gastrointestinal graft-versus-host disease

Aug 13, 2018

Dana T. Lounderfrom Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, and colleagues conducted a study to determine the role of circulating interleukin-22 (IL-22) levels in gastrointestinal graft-versus-host disease (GI GvHD) in pediatric patients undergoing hematopoietic stem cell transplant (HSCT). The study was publishedin Haematologica.

In order to assess whether IL-22 levels are elevated in pediatric patients with GI GvHD, the researchers analysed plasma samples obtained from 114 pediatric patients enrolled in a prospective cohort study, the Cincinnati Children’s Hospital Medical Center BMT repository.  At 30-days post-transplant, IL-22, IL-22 binding protein (IL-22BP), Reg3α, and IL-17 levels were analyzed using ELISA.

Patient characteristics:

  • Median age: 8 years (range, 0.4–32)
  • GvHD any site: 50 (44%)
    • Grade 1: 9 (18%)
    • Grades 2–4: 41 (82%)

Key findings:

Data is given as GvHD patients with IL levels above the median vs GvHD patients with IL levels below the median

  • IL-22
    • The cumulative incidence of new onset acute GI GvHD 30 days after HSCT: 15.5% vs8%, P= 0.04
    • 1-year treatment-related mortality (TRM) rate: 46.9% vs20%, P= 0.6
  • IL-22BP
    • IL-22BP levels negatively correlated with IL-22 levels 30 days after HSCT, r = -0.2, P= 0.03
    • There was no significant association between IL-22BP levels and the development of GI GvHD
  • IL-17
    • Incidence of GI GvHD 100 days after HSCT: 32% vs14%, P= 0.03
    • IL-17 levels significantly correlated with IL-22 levels 30 days after HSCT: r = 0.43, P< 0.0001
  • Reg3α
    • Reg3α levels negatively correlated with IL-22 levels: r = -0.22, P= 0.02
    • Reg3α levels also negatively correlated with IL-17 levels: r = -0.47, P< 0.0001


Taken together, this data indicates that IL-22 levels are elevated in patients with GI graft-versus-host disease without causing higher mortality rates in this patient population. The research group stated that because of the complex role of IL-22 as well as related molecules in the setting of post-transplant patients, further studies are required to completely clarify the method of these mechanisms.

  1. Lounder DT. et al. Interleukin-22 levels are increased in gastrointestinal graft versus host disease in children. Haematologica. 2018 May 17. DOI: 3324/haematol.2017.174771.